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Abstract
K2 and several similar purported “incense products” spiked with synthetic cannabinoids are
abused as cannabis substitutes. We hypothesized that metabolism of JWH-073, a prevalent
cannabinoid found in K2, contributes to toxicity associated with K2 use. Competition receptor
binding studies and G-protein activation assays, both performed by employing mouse brain
homogenates, were used to determine the affinity and intrinsic activity, respectively, of potential
monohydroxylated (M1, M3–M5) and monocarboxylated (M6) metabolites at cannabinoid 1
receptors (CB1Rs). Surprisingly, M1, M4 and M5 retain nanomolar affinity for CB1Rs, while M3
displays micromolar affinity and M6 does not bind to CB1Rs. JWH-073 displays equivalent
efficacy to that of the CB1R full agonist CP-55,940, while M1, M3, and M5 act as CB1R partial
agonists, and M4 shows little or no intrinsic activity. Further in vitro investigation by Schild
analysis revealed that M4 acts as a competitive neutral CB1R antagonist (Kb~40nM). In
agreement with in vitro studies, M4 also demonstrates CB1R antagonism in vivo by blunting
cannabinoid-induced hypothermia in mice. Interestingly, M4 does not block agonist-mediated
responses of other measures in the cannabinoid tetrad (e.g., locomotor suppression, catalepsy or
analgesia). Finally, also as predicted by in vitro results, M1 exhibits agonist activity in vivo by
inducing significant hypothermia and suppression of locomotor activity in mice.
In conclusion, the present study indicates that further work examining the physiological effects of
synthetic cannabinoid metabolism is warranted. Such a complex mix of metabolically produced
CB1R ligands may contribute to the adverse effect profile of JWH-073-containing products.
© 2012 Elsevier Inc. All rights reserved.
*Corresponding author. Tel.:+1 501 686 5512; fax: +1 501 686 5521. PratherPaulL@uams.edu.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
NIH Public Access
Author Manuscript
Biochem Pharmacol. Author manuscript; available in PMC 2013 April 01.
Published in final edited form as:














K2/Spice; JWH-073; CB1; cannabinoid; synthetic cannabis; obesity
1. Introduction
K2, Spice and a variety of similar “incense products” (hereafter referred to collectively as
“K2”) are currently emerging drugs of abuse with psychotropic effects mimicking those of
marijuana [1–3]. K2 is made by adulterating plant matter with any of several diverse
mixtures of synthetic cannabinoids, which are molecules that act in the brain similarly to
Δ9-tetrahydrocannabinol (Δ-THC), the major psychoactive molecule present in marijuana.
Many of the most prevalent of these synthetic cannabinoids are structurally distinct relative
to Δ-THC (Figures 1A and B) and individual K2 products are often quite variable in
composition and unpredictable in content. For example, one study details the analytical
detection of 11 different synthetic cannabinoids across 40 batches of 16 different incense
products in various combinations and proportions from brand to brand and from batch to
batch, even within brands [4]. Many K2 components were previously unregulated by
legislative authorities in the U.S., and K2 use is undetectable by standard drug urine tests.
Reportedly, these properties contribute to the motivation for K2 use by individuals seeking
to attain the mood-altering effects of cannabis, while evading detection, prosecution and
potential incarceration [5]. Compared to marijuana, K2 use is associated with an apparently
higher prevalence of severe adverse effects, such as hypertension, tachycardia,
hallucinations, agitation, seizures and panic attacks that often require immediate medical
care [6–12]. The American Association of Poison Control Centers (AAPCC) reported
handling 2,874 calls in the year 2010 regarding toxicities experienced by individuals after
using K2 [13]. Data and reports such as these prompted the United States Drug Enforcement
Administration (USDEA) to temporarily classify five common K2 synthetic cannabinoids
(JWH-018, JWH-073, JWH-200, CP-47,497, and cannabicyclohexanol) as Schedule I
substances on March 1, 2011, until greater understanding regarding the health consequences
of their use can be established [14]. Despite this ban, as of November 30, 2011, a reported
6,348 calls regarding K2 use have been made to the AAPCC in 2011 alone [15],which is
more than double the 2010 report, indicating an apparent persistence of K2 use that results
in adverse effects [5, 16]. All of these data are particularly alarming given the recent finding
that one in nine high school seniors admitted to using K2 over the past year, making K2 the
second most frequently used illicit drug, after marijuana, among high school seniors [17]
Synthetic cannabinoids found in K2, as well as Δ9-THC and other cannabinoids, induce
psychotropic effects by binding and activating cannabinoid 1 receptors (CB1Rs) in the CNS
[18, 19]. CB1Rs are G-protein coupled receptors (GPCRs) found in highest abundance in the
brain, and in lesser amounts in the liver [20], muscle and adipose tissues [21],
gastrointestinal tract [22], bone [23], and reproductive system [24]. Most scientific data
available regarding K2 to date has focused on determining product composition [4, 25],
detecting useful biomarkers for compound detection in urine and serum [26–28], and
reporting commonly observed adverse clinical effects [10, 11]. However, there is a general
lack of knowledge concerning K2 metabolism, pharmacology and toxicology.
One synthetic cannabinoid often present in K2 is JWH-073 [25, 29, 30]. JWH-073 is a
member of the JWH aminoalkylindole family, which was originally synthesized to study the
endocannabinoid system [31]. “Co-abuse” of JWH-073 with JWH-018 (a commonly abused
CB1R full agonist that is structurally similar to JWH-073) has been anecdotally reported to
reduce JWH-018-induced anxiety, resulting in a more “mellow”, cannabis-like high
compared to use of JWH-018 alone [32].
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Although little is known concerning the biotransformation of the synthetic cannabinoids
present in K2, initial studies have demonstrated that several Phase I monohydroxylated and
carboxylated metabolites of both JWH-018 and JWH-073 are the major metabolites excreted
in the urine of K2 users [26–28, 33, 34]. Recently, our laboratory reported that several
monohydroxylated JWH-018 metabolites unexpectedly retain high affinity and intrinsic
activity at CB1Rs [35], leading us to suggest that these and/or additional active metabolites
likely contribute to the mechanism of K2 toxicity. Here, we hypothesize that
biotransformation of JWH-073 produces similar metabolites (Figure 1) possessing high
affinity and/or activity at CB1Rs, resulting in complex interactions with other synthetic
cannabinoids and their metabolites present in K2. The combined action of all active
synthetic cannabinoids formed likely produces an “entourage effect” that contributes to the
increased incidence of severe adverse effects observed with K2 relative to marijuana use.
Therefore, we first examined the in vitro affinity and activity of one carboxylated and four
monohydroxylated derivatives of JWH-073 at CB1Rs. These initial findings led us to further
characterize the in vitro and in vivo pharmacology of two molecules, M1 and M4, for
potential actions as a CB1R agonist and antagonist, respectively.
2. Methods
2.1. Materials
All compounds were stored at −20°C, thawed and diluted in vehicle for use in subsequent
experiments. JWH-073, M1, M3–M6 (Figure 1) were purchased from Cayman Chemical
(Ann Arbor, MI), and diluted to a stock solution with a final concentration of either 10−2 M
(for [35S]GTPγS binding assays) or 10−3 M (for competition receptor binding) in 100%
ethanol. JWH-018 was synthesized as previously described [36–38] and validated by [1H]
Nuclear Magnetic Resonance (NMR), [13C] NMR, Distortionless Enhancement by
Polarization Transfer (DEPT)-135, Heteronuclear Single Quantum Correlation (HSQC)
spectrometry, and mass spectrometry (MS). JWH-018 was diluted to a stock solution of
10−2 M with 100% ethanol. Δ9-THC was supplied by the National Institute on Drug Abuse
(NIDA, Bethesda, MD). WIN-55,212-2, CP-55,940, AM251, and O-2050 were purchased
from Tocris Bioscience (Ellisville, MO), and SR141716 (Rimonabant) was purchased from
Cayman Chemical. AM251, O-2050, and Rimonabant were diluted to 10−2 M with dimethyl
sulfoxide (DMSO), while Δ9-THC and CP-55,940 were diluted to 10−2 M and WIN-55,
212-2 to 10−3 M in 100% ethanol. GTPγS and GDP used in the [35S]GTPγS assay were
purchased from EMD Chemical (Gibbstown, NJ) and Sigma Aldrich (St. Louis, MO),
respectively, and dissolved in water to a stock concentration of 10−2 M. Adenosine
deaminase from bovine spleen (Type IX, ammonium sulfate suspension) was purchased
from Sigma Aldrich (St. Louis, MO), and diluted in 20 mM HEPES buffer to 100 units/mL.
[3H]CP-55,940 (144.0 Ci/mmol) was purchased from Perkin Elmer (Waltham, MA) and
[35S]GTPγS (1250 Ci/mmol) was purchased from American Radiolabeled Chemicals (St.
Louis, MO). For all in vivo studies, cannabinoids were dissolved and administered in a
vehicle consisting of a 1:1:18 ratio of absolute ethanol:emulphor:physiological saline, and
injected in a volume equal to 10 mL/kg.
2.2. Membrane Preparation
Mouse brain homogenates for in vitro assays were prepared as previously described [39].
Briefly, whole brains were harvested from B6SJL mice, snap-frozen in liquid nitrogen and
stored at −80°C. On the day membrane homogenates were to be prepared, brains were
thawed on ice, then pooled in a 40 mL Dounce glass homogenizer and suspended in 5
volumes of ice cold homogenization buffer (50 mM HEPES, pH 7.4, 3 mM MgCl2, and 1
mM EGTA). Brains were then subjected to 10 complete strokes with an A pestle, followed
by centrifugation at 40,000 × g for 10 minutes at +4°C. Resulting supernatants were
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discarded, and the pellet was resuspended, homogenized and centrifuged similarly twice
more, with supernatants being discarded. For the final resuspension and homogenization
with a B pestle, ice-cold 50 mM HEPES was used in place of homogenization buffer, and
homogenates were aliquoted and stored at −80°C. Protein concentrations of homogenates
were determined using the BCA™ Protein Assay (Thermo Scientific, Rockford, IL).
2.3. Competition Receptor Binding Assay
Competition receptor binding was performed as previously described [40]. Briefly, 50 μg of
mouse brain homogenates were incubated for 90 minutes to attain equilibrium binding at
room temperature with 0.2 nM [3H]CP-55,940, 5 mM MgCl2, and either increasing
cannabinoid concentrations (0.1 nM to 10 μM), 10 μM WIN-55,212-2 (for non-specific
binding) or vehicle (for total binding), in triplicate, in a volume of 1 mL of buffer containing
50 mM Tris, 0.05% bovine serum albumin (BSA) and 1% ethanol vehicle. Reactions were
terminated by rapid vacuum filtration through Whatman GF/B glass fiber filters, followed
by five washes with ice-cold buffer (50 mM Tris, 0.05% BSA). Filters were immediately
placed into 7mL scintillation vials to which 4 mL of ScintiVerse™ BD Cocktail scintillation
fluid (Fisher Scientific, Fair Lawn, NJ) was added. Bound radioactivity was determined after
overnight incubation at room temperature and shaking, by liquid scintillation
spectrophotometry with an efficiency of 44% (Tri Carb 2100 TR Liquid Scintillation
Analyzer, Packard Instrument Company, Meriden, CT). Specific binding is expressed as
total binding minus non-specific binding, and is graphed for each data point as a percentage
of specific binding occurring in the absence of any competitor.
2.4. [35S]GTPγS Binding Assay
[35S]GTPγS binding was performed as previously described [35]. Briefly, 25 μg of mouse
brain homogenates were incubated for 30 minutes at 30°C with 0.1 nM [35S]GTPγS, 10 μM
GDP, and either cannabinoid +/− antagonist, 10 μM unlabeled GTPγS (non-specific
binding) or vehicle (total binding), in triplicate, in a volume of 1 mL of buffer containing 20
mM HEPES, 10 mM MgCl2, 100 mM NaCl, 20 units/L adenosine deaminase, 0.05% BSA
and the appropriate DMSO (0.1%) and/or ethanol (≤0.2%) vehicle. Assay buffer containing
100 mM KCl, instead of 100 mM NaCl, was used to increase basal G-protein activity in
experiments examining inverse agonism. Reactions were terminated by quick vacuum
filtration through Whatman GF/B glass fiber filters, followed by five washes with ice-cold
buffer (20 mM HEPES, 0.05% BSA). Filters were immediately placed into 7mL scintillation
vials to which 4 mL of ScintiVerse™ BD Cocktail scintillation fluid was added. Bound
radioactivity was determined after overnight incubation at room temperature and shaking by
liquid scintillation spectrophotometry with an efficiency of 93% (Tri Carb 2100 TR Liquid
Scintillation Analyzer, Packard Instrument Company, Meriden, CT). Specific binding is
expressed as picomoles of [35S]GTPγS bound per mg of protein.
2.5. Animal Care and Use
All studies were carried out in accordance with the Declaration of Helsinki and with the
Guide for Care and Use of Laboratory Animals as adopted and promulgated by the National
Institutes of Health. Experimental protocols were approved by the Animal Care and Use
Committee at the University of Arkansas for Medical Sciences (Animal Use Protocol
#3155).
Prior to surgery (see below), male NIH Swiss mice (Harlan Sprague Dawley Inc.,
Indianapolis, IN), weighing approximately 25–30 g, were housed 3 animals per Plexiglas®
cage (15.24 × 25.40 × 12.70 cm) in a temperature-controlled room in an Association for
Assessment and Accreditation of Laboratory Animal Care (AAALAC) accredited animal
facility at the University of Arkansas for Medical Sciences. Room conditions were
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maintained at 22 ± 2°C and 45–50% humidity. Lights were set to a 12-h light/dark cycle.
Animals were fed Lab Diet rodent chow (Laboratory Rodent Diet #5001, PMI Feeds, Inc.,
St. Louis, MO) and water ad libitum throughout testing. Animals were acclimated to the
laboratory environment for ~7 days prior to experiments, and to the biotelemetry chambers
for at least 2 hours prior to initiation of data acquisition. All test conditions used groups of 5
or 6 mice, and all mice were drug-naïve (with the exception of surgical anesthetics) prior to
testing.
2.6. Cannabinoid Tetrad
Cannabinoid effects on core temperature and locomotor activity were measured using
surgically-implanted biotelemetry probes. Following appropriate anesthetization with
ketamine (100 mg/kg, intraperitoneal [i.p.]) and xylazine (10 mg/kg, i.p.), the abdominal
area of each mouse was shaved and sanitized with iodine swabs. A rostral-caudal cut
approximately 1.5 cm in length was made with skin scissors, providing access to the
intraperitoneal cavity. A cylindrical glass-encapsulated radiotelemetry probe (model
ER-4000 E-Mitter, Mini Mitter Co., Inc., Bend, OR) was then inserted, and the incision was
closed using absorbable 5-0 chromic gut suture material. At least 7 days were imposed
between surgery and experimental observation of cannabinoid effects to allow incisions to
heal and mice to recover normal body weights. Following surgery, implanted mice were
individually housed in Plexiglas® mouse cages (15.24 × 25.40 × 12.70 cm) for the duration
of all temperature and locomotor activity experiments. Implanted transmitters produced
activity- and temperature-modulated signals that were transmitted to a receiver (model
ER-4000 Receiver, Mini Mitter Co., Inc., Bend, OR) underneath each mouse cage.
Receivers were housed in light- and sound-attenuating cubicles (Med Associates model
ENV-022MD, St. Albans, VT) equipped with exhaust fans, which further masked ambient
laboratory noise. On experimental days, mice were weighed, marked, and returned to their
individual cages during which at least 1 hr of baseline data were collected. Cannabinoid
doses were then calculated and prepared for injection. Animals were subsequently removed
from their cage and administered an intraperitoneal (i.p.,) injection with the indicated doses
of JWH-018, JWH-073, M1, M4, JWH-018 plus M4, or an equivalent volume of vehicle.
Mice were then placed into a new cage with fresh bedding to stimulate exploratory behavior.
Temperature and locomotor activity data were collected at regular 5-min intervals and
processed simultaneously by the Vital View data acquisition system (Mini Mitter Co., Inc.,
Bend, OR) for at least 10 hrs.
Analgesia was measured as tail-flick latency using the EMDIE-TF6 radiant heat apparatus
(Emdie Instrument Co., Montpelier, VA). For each trial, mice were positioned on the stage
of apparatus, while the tail was extended into a groove to break a photobeam. Beginning at
t=0, a button was depressed to begin a timer and illuminate a radiant heat source directed
onto the dorsal surface of the tail, approximately 2 cm from its origin from the body.
Movement of the tail at any point after the beginning of the trial broke the photobeam,
stopped both the heat source and the timer, and ended the trial. One trial per mouse per time
point was performed. Sensitivity and light intensity were set at 150 and 369, respectively
(calibrated to produce a tail flick latency between 2 and 4 seconds for untreated mice), and
maximum time for each trial was 10 seconds. Tail-flick latency was measured at 0, 10, 30,
and 60 minutes after either cannabinoid or vehicle administration.
Catalepsy was measured by the horizontal bar test, which utilized a cylindrical steel bar (0.5
cm in diameter) that was suspended 4.0 cm above and horizontal to a Plexiglas platform. To
begin the test trial, a mouse was positioned with its forelimbs on the horizontal bar and its
hindlimbs on the platform, in such a way that the mouse assumed a rearing posture. Upon
placement on the catalepsy bar, a timer was started, and counted until the mouse removed
both of its paws from the bar and assumed a non-rearing posture. A single trial per mouse
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per time point was performed, and the maximum time allowed on the bar was 30 seconds.
Catalepsy scores were measured at 0, 10, 30 and 60 minutes after administration of vehicle
or cannabinoid.
2.7. Statistical Analysis
Curve fitting and statistical analyses for in vitro experiments were performed using
GraphPad Prism version 5.0b (GraphPad Software Inc., San Diego, CA). The Cheng-Prusoff
equation [41] was used to convert the experimental IC50 values obtained from competition
receptor binding experiments to Ki values, a quantitative measure of receptor affinity. Non-
linear regression for one-site competition was used to determine the IC50 for competition
receptor binding. Curve fitting of concentration-effect curves via non-linear regression was
also employed to determine the EC50 (a measure of potency) and Emax (a measure of
efficacy) for [35S]GTPγS concentration-effects experiments. A power equation based on the
Cheng-Prusoff equation was used to determine the Kb of M4 from its IC50 to inhibit an EC90
concentration of CP-55,940 [42]. Schild analysis as previously described by Thomas, et. al.
[43] was also performed to determine Kb and Schild slope for the ability of M4 to shift the
JWH-018 concentration effect curves for G-protein activation. Data are expressed as mean ±
SEM. The Student’s t-test was used to determine statistical significance (P<0.05) between
two groups, while a one-way ANOVA, followed by Tukey’s Multiple Comparison post-hoc
test, was used to determine statistical significance (P<0.05) between three or more groups.
For core body temperature experiments, the area under the curve (AUC) was calculated
using a trapezoidal rule from 0–500 minutes, and statistical significance (P<0.05) was
determined using a one-way ANOVA, followed by Tukey’s HSD post-hoc test. For
locomotor activity, total locomotor counts were summed from 0–800 minutes. Because
locomotor, analgesia and catalepsy data were not normally distributed, Kruskal-Wallis one-
way ANOVA on ranks were performed, and all pair-wise comparisons were then made
using the Tukey’s HSD tests. In vivo statistical calculations were performed using
SigmaStat 3 (Systat Software, Inc., San Jose, CA).
3. Results
3.1. JWH-073, M1, M4, and M5 bind to CB1Rs with intermediate to high affinity
Saturation binding experiments using the radiolabeled, high-affinity cannabinoid agonist
[3H]CP-55,940 determined that mouse brain homogenates employed for these experiments
contain a CB1R density of 2.44 ± 0.15 pmol/mg protein, to which [3H]CP-55,940 binds with
a Kd of 0.37 ± 0.07 nM (n=3). To determine the affinity (Ki) of JWH-073, M1, and M3–M6
(Figure 1) for CB1Rs, initial competition receptor binding studies with [3H]CP-55,940 were
conducted (Figure 2, Table 1). Specifically, the ability of increasing concentrations of each
compound to displace [3H]CP-55,940 from CB1Rs present in mouse brain homogenates was
examined. In agreement with previous reports [44], JWH-073 bound to CB1Rs with high
affinity (12.9 ± 3.4 nM, n=6, Table 1). Interestingly, M1 also displayed remarkably high
affinity for CB1Rs, equivalent to that of the parent compound (14.1 ± 3.5 nM, n=3). The
affinities of M4 and M5 for CB1Rs were slightly lower, but still in the intermediate
nanomolar range (122.2 ± 16.2 nM and 224.2 ± 9.0 nM, respectively, n=3–4), predicting
that even if relatively low concentrations of these compounds are formed via metabolism,
they likely produce physiologically relevant effects via binding and modulation of CB1R
activity in vivo. M3 bound to CB1Rs with a low micromolar affinity (1.28 ± 0.47 μM, n=4),
while concentrations of M6 as high as 10 μM produced less than 10% displacement of
[3H]CP-55,940 specific binding (n=3), signifying little or no CB1R affinity.
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3.2. M1, M3 and M5 act as CB1R partial agonists with equivalent efficacy to stimulate G-
protein activity, while M4 lacks intrinsic activity
The intrinsic activity of JWH-073, M1, and M3–M6 at CB1Rs was next determined by
employing the [35S]GTPγS binding assay, which measures G-protein activation, in mouse
brain homogenates. Initially, the G-protein activation induced by a receptor-saturating
concentration (10 μM) of each compound was examined (Figure 3A, Table 2). JWH-073
displayed equivalent efficacy relative to the full CB1R agonist, CP-55,940 (0.28 ± 0.03 vs.
0.32 ± 0.02 pmole/mg, respectively, n=3–5). M1, M3 and M5 surprisingly retained partial
agonist activity (0.14 ± 0.01, 0.11 ± 0.02, and 0.16 ± 0.02 pmole/mg, respectively, n=3–4),
producing greater than or equivalent activation of G-proteins relative to that produced by
Δ9-THC (0.08 ± 0.00 pmole/mg). In contrast, M4 and M6 produced negligible G-protein
activation in mouse brain homogenates. Interestingly, 10 μM THC (Figure 3A) produces
less G-protein activation than a 1 μM concentration (Figure 3B). These data parallel our
observations that in this assay, under these experimental conditions, THC consistently
exhibits a bi-phasic concentration-effect curve with concentrations greater than 1 μM
producing less activation than lower concentrations examined (see Figure 4).
To confirm that CP-55,940, JWH-073, M1, M3 and M5 produced G-protein activation via
specific interaction with CB1Rs, the effect of co-administration with a CB1R-selective
neutral antagonist O-2050 (1 μM) to attenuate EC90 concentrations (1 μM for all
compounds except CP-55,940, which instead was 100 nM) of the cannabinoids was
examined (Figure 3B, Table 2). The increase in [35S]GTPγS binding produced by each of
these agonists was significantly reduced by O-2050, indicating that these compounds all
activated G-proteins in mouse brain homogenates by a CB1R-dependent mechanism.
Concentration-effect studies were conducted to determine a measure of potency (e.g., EC50)
for G-protein activation by M1 and to further validate a receptor-mediated mechanism for
the intrinsic activity reported (Figure 4, Table 1). As anticipated, G-protein activation
produced by CP-55,940, JWH-073, Δ9-THC and M1 was concentration-dependent, with
maximal efficacies (e.g., Emax values) that agree well with data presented in Figure 3A.
Collectively, these data indicate that CP-55,940 and JWH-073 act as full CB1R agonists,
while M1, M3 and M5 exhibit partial agonist activity, and M4 lacks significant intrinsic
activity at CB1Rs.
3.3. M4 acts as an in vitro competitive neutral antagonist at CB1Rs with nanomolar
potency (Kb)
Although M4 bound with intermediate nanomolar affinity to CB1Rs (e.g., 122 nM; Figure
2), it neither significantly activated nor inhibited basal G-protein activity and thus was
devoid of intrinsic activity as measured by this functional assay (Figure 3). These combined
observations intriguingly predict that M4 might serve as a physiologically relevant neutral
antagonist at CB1Rs; hence it was selected for further characterization. First, concentrations
of M4 alone ranging from 0.1 nM to 10 μM neither significantly increased (characteristic of
agonists), nor decreased (characteristic of inverse agonists), basal [35S]GTPγS binding
levels (Figure 5A). These observations indicate that M4 may act as a neutral CB1R
antagonist concerning G-protein regulation in mouse brain homogenates. Second, the ability
of co-administration with a receptor saturating concentration of M4 (10 μM) to antagonize
effects on G-protein activity produced by three different CB1R agonists (Figure 5B) or two
CB1R inverse agonists (Figure 5C) was examined. In all cases, co-incubation with M4
significantly antagonized the action of agonists (to increase) or inverse agonists (to reduce)
[35S]GTPγS binding. Third, a measure of the potency of CB1R antagonism produced by M4
was investigated by determining the antagonist dissociation constant (e.g., Kb) at CB1Rs, for
two different agonists employing two alternative but complementary methods (Figure 6).
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Initially, the ability of increasing concentrations of M4 to reduce [35S]GTPγS binding
induced by a single EC90 concentration of CP-55,940 (100 nM) in mouse brain homogenates
was conducted (Figure 6A). Co-incubation with M4 produced a concentration-dependent
decrease in CP-55,940-induced [35S]GTPγS binding. Conversion of the IC50 of this curve to
a measure of antagonist potency by employing a modified function of the Cheng-Prusoff
equation [42], revealed a Kb value 40.3 nM for M4. Schild analysis [43] was additionally
conducted to determine not only the Kb value of M4, but also whether M4 produces
competitive or non-competitive antagonism at CB1Rs (Figure 6B). Since JWH-073 and
JWH-018 are often co-abused, as noted by their concurrent presence in K2 products, as well
as accounts of users combining JWH-018 with JWH-073 in deliberate ratios [32], we
examined the ability of M4 to antagonize the G-protein activation produced by JWH-018.
The ability of three different M4 concentrations (1, 3, and 10 μM) to shift the [35S]GTPγS
binding curve produced by JWH-018 was investigated (Figure 6B). M4 produced a
concentration-dependent shift-to-the-right of the JWH-018 curve without affecting maximal
efficacy. Specifically, JWH-018 alone activates G-proteins with an EC50 of 8 nM, which is
in close agreement with data previously published [35]. However, in the presence of
increasing concentrations of M4, the EC50 of JWH-018 increased to 178, 263, and 1562 nM.
This yielded a Schild plot with a slope of 0.97 (Figure 6B, inset) and a Kb of 48.1 nM. This
value is in close agreement with the Kb determined in Figure 6A (e.g., 40.3 nM) and, most
importantly, clearly indicates that M4 is a potent, competitive antagonist at CB1Rs.
3.4. M1 displays JWH-073-like activity in vivo
M1 was tested in NIH Swiss Mice for effects on two well-established cannabinoid
endpoints, core body temperature and locomotor activity, as was similarly performed in our
previous study examining JWH-018 and its M1 derivative [35]. As reported in that study,
cannabinoids induce hypothermia and suppress locomotor activity [45]. In the present study,
mice were implanted with telemetry probes that simultaneously measure core body
temperature and locomotor activity as described previously in the “Methods” section.
Administration of JWH-073 or M1 (10 mg/kg, i.p.) resulted in sharp drops in core body
temperature, with the minimum temperatures recorded being 29.74 ± 1.44°C for JWH-073
and 30.32 ± 0.66°C for M1 (Figure 7A). Time to maximal core body temperature reduction
(Tmax) did not differ for the two cannabinoids examined (54.17 ± 5.23 minutes for the parent
compound and 58.00 ± 4.64 minutes for M1), suggesting a similar pharmacokinetic profile.
Simultaneously, M1 resulted in a reduction of locomotor activity similar to that observed
with administration of JWH-073 (Figure 7B). Taken together, these data suggest that M1
retains a substantial portion of the in vivo activity exhibited by the parent compound.
3.5. M4 antagonizes JWH-018-induced hypothermia in vivo
The observation that M4 behaves as a neutral, competitive CB1R antagonist in vitro
prompted the investigation of its potential CB1R antagonist activity in vivo. In the following
experiments, M4 (10 mg/kg, i.p.) was co-administered in NIH Swiss mice with JWH-018 (3
mg/kg, i.p.) to determine if M4 antagonizes four different measures of in vivo cannabinoid
activity, commonly known as the cannabinoid tetrad: hypothermia, locomotor activity
suppression (both described in the previous subsection), analgesia, and catalepsy. Previous
work in this model showed that JWH-018 (3 mg/kg, i.p.) significantly decreases core body
temperature and locomotor activity [35]. Initially, a dose of 10 mg/kg, i.p., of M4 was
administered to test its antagonism of the hypothermic effects induced by JWH-018 (3 mg/
kg, i.p.). This dose of M4 was chosen for initial in vivo experiments because of the striking
cannabimimetic effects elicited by 10 mg/kg, i.p. of the structurally similar M1 derivatives
of both JWH-018 [35] and JWH-073 (see previous subsection). In the present study, 3 mg/
kg of JWH-018 administered i.p. produces hypothermia as indicated by a maximal decrease
in core body temperature to 30.28 +/− 0.71 °C (Figure 8A). In marked contrast, M4 resulted
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in no significant change in body temperature. Significantly, hypothermia induced by
JWH-018 was blunted by co-administration with M4 (to 33.09 +/− 0.70 °C). Although co-
administration with M4 did not completely prevent the reduction in body temperature
produced by JWH-018, it did significantly blunt JWH-018-induced hypothermia (Figure
8B). Quantification of this effect is indicated by summation of area under the curve (AUC)
data generated 0–500 minutes after injection. Most importantly, these data demonstrate that
M4 acts as a CB1R antagonist not only in vitro, but also in vivo.
Potential antagonism of other JWH-018-induced effects (analgesia, catalepsy, and locomotor
suppression) by this dose of M4 was also examined. Coadministration of M4 with JWH-018
(3 mg/kg, i.p.,) showed no difference in these assays from JWH-018 alone (Figure 9). In all
cases, the overall ANOVA was significant due to main effects of time (P=0.002 for
locomotor activity. P=0.004 for analgesia, and P=0.003 for catalepsy), but there were no
between-group comparisons at any time point that reached statistical significance.
Discussion
This study is the first to report that potential monohydroxylated metabolites of JWH-073
retain physiologically relevant, high (M1), intermediate (M4 and M5) and low (M3) affinity
for CB1Rs. M1, M3, and M5 also activate G-proteins in a CB1R-dependent manner with
partial agonist activity equivalent to that produced by the major psychoactive constituent in
marijuana, Δ9-THC. M1 was further characterized for potential in vivo activity and, similar
to JWH-073, induces hypothermia and suppresses locomotor activity in mice. M4 was also
importantly shown to act as a novel competitive neutral CB1R antagonist. Specifically,
[35S]GTPγS binding experiments demonstrate that co-incubation with M4 blocks
modulation of CB1R activity by both agonists and inverse agonists, with no effect on basal
G-protein activity when tested alone. M4 antagonizes CB1R-mediated G-protein activation
by JWH-018 in a competitive manner with a Kb value of 48 nM. Finally, M4 attenuates
JWH-018-induced hypothermia in mice, while an equivalent dose does not antagonize other
CB1R-dependent effects that are entirely mediated by CNS-specific CB1Rs. Both in vitro
and in vivo data presented collectively indicate that metabolism of JWH-073 may produce a
complex mix of metabolites exhibiting a range of CB1R intrinsic activity that work “in
concert” to contribute to the biological actions of JWH-073-containing products.
Furthermore, the neutral CB1R antagonist properties of M4 suggest that this molecule might
serve as a scaffold for development of a novel class of anti-obesity drugs (discussed below).
The first novel finding reported here is that M1 and M5 retain high and intermediate affinity
for CB1Rs, respectively. Furthermore, both compounds act in vitro as agonists at CB1Rs,
while M1 was also shown to demonstrate CB1R agonist activity in vivo. If future
comprehensive pharmacokinetic studies confirm that metabolism of JWH-073 produces
multiple active metabolites with significant CB1R affinity and activity (such as the ones
examined in the present study), these acute actions could result in prolonged, excessive
activation of CB1Rs. Furthermore, additive or synergistic actions exerted by multiple active
metabolites, combined with the agonist activity of other synthetic cannabinoids present in
K2 products, could potentially result in adverse effects rarely observed with marijuana, since
Δ9-THC is metabolized to only one reported major active metabolite [46].
In addition to acute actions, sustained elevations of active cannabinoids following chronic
K2 abuse would be expected to produce adaptive alterations in CB1R signaling [18, 47–49]
that might interfere with normal endocannabinoid function. For example, prolonged
endocannabinoid dysregulation could disrupt a wide variety of physiological functions
including mood and cognition [50], appetite and energy homeostasis [51, 52], pain sensation
[53], immune function [54], bone homeostasis [23] and reproduction [24]. In support of this
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suggestion, many similar adverse effects are observed following chronic cannabis use [55–
57].
It is also possible that prolonged exposure to K2 synthetic cannabinoids and their active
metabolites may promote K2 dependence, characterized by a withdrawal syndrome upon
abrupt cessation of use. Although the subject of cannabis dependence and withdrawal
remains controversial, reliable evidence has accumulated to define a specific marijuana
withdrawal syndrome in human subjects [58], occurring with a prevalence of approximately
9% in regular marijuana users [59]. Selective reduction in the density of cortical CB1Rs has
also been reported in chronic cannabis users [60]. Such CB1R down-regulation would
presumably result in reduced CB1R signaling, potentially contributing to the development of
tolerance. It could therefore be predicted that chronic use of higher efficacy cannabinoids
present in K2, coupled with the sustained action of associated active metabolites, might
produce similar or even greater adaptations leading to enhanced levels of tolerance and/or
dependence relative to chronic cannabis use.
If metabolism of JWH-073 results in accumulation of physiologically relevant
concentrations of the CB1R antagonist M4 in the CNS, first-time exposure to JWH-073-
containing products may acutely precipitate withdrawal in high-intake cannabis and K2
users. In support of this hypothesis, it is interesting that symptoms of cannabis withdrawal
resemble several adverse effects associated with K2 use (e.g., anxiety, aggression,
irritability, hypertension) [61, 62]. High concentrations of M4 accumulating in the CNS
could also promote compensatory escalations in K2 use in order to maintain the subjective,
reinforcing effects of K2 use, while production of low or moderate concentrations of this
antagonist may explain the “mellowness” attributed to JWH-073 relative to other synthetic
cannabinoids [63]. In any case, both acute and chronic cellular responses resulting from use
of JWH-073-containing products are possibly influenced by actions produced by a
combination of the parent compound and its active metabolites.
Overactivity of the endocannabinoid system appears to contribute to development of obesity
and metabolic syndrome [64]. As such, CB1R antagonists/inverse agonists showed great
promise as anti-obesity agents. However, the first-in-class drug rimonabant was denied
approval by the United States Food and Drug Administration (USFDA) and was
subsequently removed from the European drug market due to severe psychiatric side effects,
including depression, anxiety, and increased risk of suicide [65]. Although antagonism of
endocannabinoids acting at CB1Rs in the CNS by rimonabant may cause these adverse
reactions [66], recent evidence instead suggests that such psychiatric complications may be
primarily associated with inverse agonist properties of these compounds that reduce the
constitutive activity of CB1Rs in the CNS [67]. The majority of CB1R antagonists identified
to date unfortunately possess inverse agonist activity [68]. However, recent studies in mice
demonstrate that compounds acting as neutral CB1R antagonists (and not inverse agonists)
also possess anti-obesity properties, but with reduced side effects relative to rimonabant [69,
70]. Therefore, the findings reported here that M4 is a neutral CB1R antagonist suggests that
this molecule might serve as a scaffold for development of anti-obesity drugs that reduce an
aberrantly high level of endocannabinoid signaling in obese individuals without altering
constitutive CB1R activity, possibly resulting in fewer CNS effects.
CB1R antagonists with limited brain penetration also are efficacious anti-obesity agents with
reduced adverse psychiatric effects [71]. Notably, M4 blunted, but did not completely block,
CB1R-induced hypothermia (Figure 8). Furthermore, M4 curiously failed to antagonize
other CB1R-mediated effects in the cannabinoid tetrad (Figure 9). These observations might
be explained, in part, by a less than adequate dose of M4 selected for the in vivo antagonism
studies. However, it is also tempting to speculate that M4 does not readily enter the brain to
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antagonize centrally mediated effects of JWH-018 (e.g., analgesia, catalepsy, and locomotor
suppression), but can partially antagonize the effect of CB1R-induced hypothermia, which
has been shown to be mediated, in part, by peripheral CB1Rs [72]. Further pharmacokinetic
experiments will be required to validate the potential peripherally-restricted properties of
M4 before definitive conclusions can be made.
Our group recently reported that several monohydroxylated metabolites of the synthetic
cannabinoid JWH-018 retain high CB1R affinity and activity [35]. The current report
similarly examined the affinity and activity of several potential JWH-073 metabolites at
CB1Rs. Although the present study shows that potential monohydroxylated metabolites of
JWH-073 also retain significant affinity and activity, a distinct difference between reports is
discovery of M4: a neutral CB1R antagonist with nanomolar affinity and potential
significance for development of anti-obesity therapeutics. Regardless of intrinsic activity,
metabolites retaining high CB1R affinity have potential to exaggerate or disrupt cannabinoid
signaling. The finding that multiple JWH-073 candidate metabolites retain high CB1R
affinity and exhibit a range of intrinsic activity provides valuable mechanistic insight and
suggests that biotransformation of K2 may contribute to the relatively high rate of severe
adverse effects often reported with use of this rapidly emerging drug of abuse.
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Figure 1. Cannabinoids examined in the present study
A. Structures of significant cannabinoids discussed and utilized in the present work. B.
Structures of JWH-073 [(1-butyl-1H-indole-3-yl)-1-naphthalenyl-methanone] and its
potential metabolites, here designated M1 [(1-butyl-4-hydroxy-1H-indole-3-yl)
(naphthalen-1-yl-methanone], M3 [(1-butyl-6-hydroxy-1H-indole-3-yl)(naphthalen-1-yl-
methanone], M4 [(1-butyl-7-hydroxy-1H-indole-3-yl)(naphthalen-1-yl-methanone], M5 [1-
(4-hydroxybutyl-1H-indole-3-yl)(naphthalen-1-yl)-methanone] and M6 ([4-(3-(1-
naphthoyl)-1H-indole-1-yl)-1-butanoic acid]), examined for CB1R affinity and activity.
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Figure 2. JWH-073, M1, M3, M4, M5, but not M6, bind to CB1R receptors
In competition receptor binding assays, JWH-073, M1, M3, M4, and M5 completely
displaced [3H]CP-55,940 from CB1Rs in mouse brain homogenates with nanomolar
(JWH-073, M1, M4, M5) to micromolar (M3) affinity, while M6 displaced less than 10%
[3H]CP-55,940 specific binding, signifying M6 has little or no CB1R affinity (n=3–6).
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Figure 3. JWH-073, M1, M3 and M5, but not M4, activate CB1Rs in mouse brain homogenates
A. A receptor-saturating concentration (10 μM) of JWH-073 in the [35S]GTPγS binding
assay activated G-proteins in mouse brain homogenates with full agonist activity equivalent
to that produced by CP-55,940. M1, M3 and M5, but not M4 or M6, activate G-proteins
with efficacy equivalent to that produced by Δ9-THC. Values designated by different letters
are significantly different (P<0.05, one way ANOVA with Tukey’s Multiple Comparison
post-hoc test, mean ± SEM, n=3–8). B. Activation of G-proteins in mouse brain
homogenates by JWH-073, M1, M3, and M5 (1 μM, solid bars) was significantly attenuated
by co-incubation with the CB1R-selective antagonist O-2050 (1 μM, checkered bars),
signifying that JWH-073, M1, M3 and M5 activate G-proteins via CB1Rs. (*P<0.05,
**P<0.01, ***P<0.001 vs. cannabinoid alone, Student’s t-test, mean ± SEM, n=3–6) Note:
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Because of its higher CB1R affinity, 100 nM, instead of 1 μM, of CP-55,940 was used in
the CB1R blockade assay.
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Figure 4. G-protein activation by JWH-073 and M1 via CB1Rs is concentration-dependent
The potency and maximal efficacy of CP-55,940, JWH-073, M1, and Δ9-THC to activate
CB1Rs in mouse brain homogenates were determined employing the [35S]GTPγS binding
assay (mean ± SEM, n=3–4).
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Figure 5. M4 antagonizes the actions of both CB1R agonists and inverse agonists in mouse brain
homogenates, while having no activity when tested alone
A. In the [35S]GTPγS binding assay, M4 when examined alone, up to 10 μM
concentrations, showed neither agonist nor inverse agonist activity in mouse brain
homogenates. B. M4 (10 uM) blocked the activity produced by CB1R agonists (100 nM CP,
1 μM JWH-018, and 500 nM JWH-073) and C. inverse agonists (10 μM Rimonabant and
AM251) (*P<0.05, **P<0.01, ***P<0.001 vs. cannabinoid alone, Student’s t-test, mean ±
SEM, n=3–6; †, ‡ These data are of the same data presented in figures 6A[†] and 6B[‡].)
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Figure 6. M4 acts as an in vitro competitive neutral antagonist at CB1Rs
A. M4 blocks CB1R activation of G-proteins produced by an EC90 concentration of
CP-55,940 in mouse brain homogenates with a nanomolar Kb. B. Schild analysis of the
concentration-dependent antagonism of JWH-018 by M4 yielded a nanomolar Kb and a
slope (not significantly different that 1) that indicates a competitive mechanism of
antagonism (inset). The arrow indicates significant rightward-shifts in the potency of G-
protein activation produced by JWH-018 in response to co-administration with increasing
concentrations of M4.
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Figure 7. M1 induces hypothermia and locomotor suppression similar to JWH-073
Time course telemetry data shows that both JWH-073 (10 mg/kg, i.p., black circles) and M1
(10 mg/kg, i.p. gray circles) produce A. robust hypothermia, and B. locomotor suppression,
relative to vehicle control. This indicates that M1 retains the partial-to-full potency and
efficacy of JWH-073 to produce hypothermia and locomotor suppression. Arrow indicates
time of vehicle or cannabinoid administration.
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Figure 8. M4 blunts JWH-018 induced hypothermia in mice
A. Time course telemetry data after administration of JWH-018 (3 mg/kg, i.p., black
circles), M4 (10 mg/kg, i.p., gray circles), or co-administration of these doses (white
circles). Arrow indicates time of vehicle or cannabinoid administration. B. Area under the
curve summation of telemetry data collected 0–500 minutes after vehicle or cannabinoid
administration shows that M4 significantly attenuated hypothermia induced by JWH-018,
indicating that M4 displays CB1R antagonism in vivo. (*P<0.05 vs. vehicle, #P<0.05 vs.
JWH-018 alone, one-way ANOVA with Tukey HSD test, mean ± SEM, n=5).
Brents et al. Page 24













Figure 9. M4 does not antagonize analgesia, catalepsy or locomotor suppression induced by
JWH-018
Administration of JWH-018 (3 mg/kg, i.p., black circles) produces A. robust analgesia (tail
flick assay), B. catalepsy, and C. locomotor suppression. Co-administration of M4 (10 mg/
kg, i.p., white circles) does not significantly alter any of the JWH-018-induced effects
(P<0.05, one-way ANOVA with Tukey HSD test, mean ± SEM, n=5–6).
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Table 1
Comparison of CB1R affinity with potency and efficacy for G-protein activation produced by cannabinoid
ligands
[3H]CP binding [35S]GTPγS Binding
Drug Ki (nM) EC50 (nM) Emax (pmole/mg)
CP-55,940 0.26 ± 0.1† 7.5 ± 1.8 0.26 ± 0.01a
JWH-073 12.9 ± 3.4 276.5 ± 65.3 0.27 ± 0.01a
M1 14.1 ± 3.5 112.9 ± 29.2 0.14 ± 0.01b
Δ9-THC 15.3 ± 4.5† 77.0 ± 29.9 0.08 ± 0.01c
†
Values previously reported [35]
a,b,c
Values designated by different letters are significantly different.
P<0.05, one-way ANOVA, Tukey Post-hoc test; Reported as mean ± SEM, n=3–4
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Table 2
G-protein activation by JWH-073 and metabolites, and blockade by the selective CB1R antagonist O-2050
Drug [35S]GTPγS Binding (pmole/mg)
10 μM 1 μM 100 nM + O-2050 (1 μM)†
Δ9-THC 0.08 ±0.00 a,b 0.17 ± 0.01 ND 0.06 ± 0.01***
CP-55,940†† 0.32 ± 0.02 c, ND 0.20 ± 0.04 0.06 ± 0.03**
JWH-073 0.28 ± 0.03c 0.27 ± 0.04 ND 0.07 ± 0.02**
M1 0.14 ± 0.01a 0.17 ± 0.01 ND 0.07 ± 0.01**
M3 0.11 ± 0.02a,b 0.04 ± 0.00 ND 0.02 ± 0.01*
M4 0.04 ± 0.01b ND ND ND
M5 0.16 ± 0.02a 0.12 ± 0.00 ND 0.05 ± 0.01***
M6 0.03 ± 0.01b ND ND ND
a,b,c
Values designated by different letters are significantly different.
P<0.05, one-way ANOVA with Tukey’s post-hoc test, reported as mean ± SEM, n=3–8;
†
Emax of O-2050 alone (1 μM) = 0.05 ± 0.01
††






P<0.001, vs. drug alone, Student’s t-test, reported as mean ± SEM, n=3–9.
ND, Not Determined
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